Monday, January 02, 2012 8:07:17 PM
Alexander Fleming Award Winners
Current Winner
BARTON F. HAYNES, MD, FIDSA, a thought leader in the fields of human host-pathogen interactions and immune reconstitution, is the recipient of IDSA’s 2011 Alexander Fleming Award for Lifetime Achievement. This award recognizes a career that reflects major contributions to the acquisition and dissemination of knowledge of infectious diseases. Dr. Haynes has been a pioneer in the development of a vaccine for HIV. Through his seminal work in the biology of human thymic epithelium and thymocytes, he has enriched our understanding of human thymic function and established the foundation for thymic cell transplantation for the curative treatment of DiGeorge Syndrome.
Dr. Haynes is the Hanes Professor of Medicine and Immunology and director of the Duke Human Vaccine Institute. His research during the last 10 years has focused on the development of an HIV-1 vaccine. Through his work, Dr. Haynes has demonstrated the importance of tolerance and other immunoregulatory mechanisms in hampering the development of broadly neutralizing antibodies against HIV-1, launching HIV vaccine development into a new direction.
After receiving his medical degree from Baylor College of Medicine in 1973, Dr. Haynes completed his medical residency and internship at Duke Hospital in Durham, North Carolina. From 1975 to 1980, he worked in various roles at the National Institute of Allergy and Infectious Diseases. In July 1980, he began teaching at Duke University in the Departments of Medicine and Microbiology and Immunology. In 2005, he was named director of the National Institutes of Health Center of HIV/AIDS Vaccine Immunology (CHAVI), an international consortium of scientists with the task of developing an effective HIV-1 vaccine. Under his leadership, CHAVI has defined the early T cell responses to HIV and their protective nature, provided the most extensive assessment of HIV antibody responses during acute HIV infection, and developed vaccine candidates that are entering clinical trials. Dr. Haynes has published more than 480 journal articles and served on the editorial boards of numerous scientific publications such as the Journal of Clinical Immunology and Blood.
In recognition of his outstanding contributions to the field of infectious diseases and immunology for more than 30 years—from his groundbreaking research to develop thymus transplantation for T cell deficiency to his work to develop a vaccine for HIV/AIDS—IDSA is proud to present Dr. Haynes with the 2011 Alexander Fleming Award for Lifetime Achievement.
http://www.idsociety.org/Alexander_Fleming_Award_Winners/
Recent CDMO News
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 11/12/2024 09:15:31 PM
- Rowley Law PLLC is Investigating Proposed Acquisition of Avid Bioservices, Inc. • PR Newswire (US) • 11/07/2024 10:55:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 11/07/2024 02:59:47 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 11/07/2024 02:42:14 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2024 02:11:21 AM
- Avid Bioservices to be Acquired by GHO Capital Partners and Ampersand Capital Partners in $1.1 Billion Transaction • GlobeNewswire Inc. • 11/06/2024 11:04:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/17/2024 08:45:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/15/2024 11:40:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/11/2024 11:38:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/11/2024 11:38:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/11/2024 11:37:48 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 10/11/2024 12:22:11 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 10/11/2024 12:21:22 AM
- Avid Bioservices to Participate in Craig-Hallum Bioprocessing Conference • GlobeNewswire Inc. • 09/12/2024 08:05:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 09/09/2024 08:43:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/09/2024 08:19:30 PM
- Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2024 • GlobeNewswire Inc. • 09/09/2024 08:05:31 PM
- U.S. Futures Rise Amid Inflation Report Anticipation; Oil Prices Climb on Hurricane Threat and Supply Concerns • IH Market News • 09/09/2024 10:09:14 AM
- Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2025 After Market Close on September 9, 2024 • GlobeNewswire Inc. • 09/03/2024 08:05:20 PM
Alliance Creative Group (ACGX) Releases Q3 2024 Financial and Disclosure Report with an increase of over 100% in Net Income for 1st 9 months of 2024 vs 2023 • ACGX • Nov 14, 2024 8:30 AM
Unitronix Corp. Publishes Its Cryptocurrency Portfolio Strategy • UTRX • Nov 14, 2024 8:05 AM
Avant Technologies and Ainnova Tech Form Joint Venture to Advance Early Disease Detection Using Artificial Intelligence • AVAI • Nov 12, 2024 9:00 AM
Swifty Global Announces Launch of Swifty Sports IE, Expanding Sports Betting and Casino Services in the Irish Market • DRCR • Nov 12, 2024 9:00 AM
Oohvie App Update Enhances Women's Health with Telemedicine and Online Scheduling • HLYK • Nov 11, 2024 8:00 AM
SANUWAVE Announces Record Quarterly Revenues: Q3 FY2024 Financial Results • SNWV • Nov 8, 2024 7:07 AM